AstraZeneca PLC Directorate Change (0369G)
July 22 2021 - 2:00AM
UK Regulatory
TIDMAZN
RNS Number : 0369G
AstraZeneca PLC
22 July 2021
22 July 2021 07:00 BST
Non-Executive Board appointment
AstraZeneca PLC announced today that the Board has appointed
Andreas Rummelt as a Non-Executive Director, following the
completion yesterday of its acquisition of Alexion Pharmaceuticals,
Inc.
Dr. Rummelt has been a member of the Board of Alexion since
2010. His effective date of appointment to AstraZeneca's Board is 1
August 2021, the same as that of AstraZeneca's new Executive
Director and Chief Financial Officer, Dr. Aradhana Sarin (formerly
Executive Vice-President, Chief Financial Officer of Alexion), as
previously announced on 4 June 2021.
Leif Johansson, Chairman of AstraZeneca said, "We are delighted
to welcome Andreas to AstraZeneca and look forward to working with
him. His extensive experience of the pharmaceutical industry and in
particular his technical R&D, manufacturing and quality
assurance expertise, together with his deep knowledge of Alexion,
will enable him to make a significant contribution to the Board's
work."
Biographical details - Andreas Rummelt
Dr. Andreas Rummelt has more than 20 years' experience in
executive management positions in the pharmaceutical industry. His
international career has focused on technical research and
development, manufacturing and quality, as well as a period leading
a generics business as Chief Executive Officer. He is now Chairman
and Managing Partner of InterPharmaLink AG, a management consulting
firm based in Basel, Switzerland.
Dr. Rummelt was Group Head of Technical Operations and Quality
at Novartis and, from 2006 until 2010, served as a member of the
Executive Committee there. He originally joined Sandoz Pharma in
Basel, Switzerland in 1985 and held various positions of increasing
responsibility in Pharma Development, including Head of Worldwide
Technical Research and Development. From 1999, Dr. Rummelt served
as Global Head of Technical Operations and Quality of the
Pharmaceuticals Division of Novartis, and from 2004 to 2008, as
Global Chief Executive Officer of Sandoz, the Generics Division of
Novartis.
Dr. Rummelt has served as a Director of Alexion Pharmaceuticals,
Inc. since 2010 and is a member of the boards of various
privately-held biotech and pharmaceutical companies in Europe. He
is also member of the Scientific Advisory Committee of the Global
Antibiotic Research and Development Partnership based in Geneva,
Switzerland.
Dr. Rummelt is a pharmacist and earned his PhD in pharmaceutical
sciences from the University of Erlangen-Nuremberg, Germany. He
received his executive training in general management and
leadership from IMD in Lausanne, Switzerland; INSEAD in
Fontainebleau, France; and Harvard Business School in Cambridge, MA
in the US.
No disclosure obligations arise under paragraphs (1) to (6) of
LR 9.6.13 R of the Financial Conduct Authority's Listing Rules in
respect of this appointment.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology, Rare Diseases and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries, and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
ENDS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASEIFIFEFSEEW
(END) Dow Jones Newswires
July 22, 2021 02:00 ET (06:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024